Search research articles
Contact Us
Filters
Showing results (101-110 of 139) with videos related to
Page
of 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
November 17, 2023
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort
Angéline Galvin, Coralie Courtinard, Fanny Bouteiller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
Hans Wildiers, Anne Armstrong, Eveline Cuypere, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2019
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup
Véronique D'Hondt, Jean-Luc Canon, Lise Roca, et al.
Lancet (London, England)
|
August 2, 2025
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial
Etienne Brain, Olivier Mir, Emmanuelle Bourbouloux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 11, 2017
Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper
Matti Aapro, Alain Astier, Riccardo Audisio, et al.
The Oncologist
|
August 17, 2023
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
Fanny Le Du, Matthieu Carton, Thomas Bachelot, et al.
Genome Medicine
|
March 16, 2021
Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study
Céline Callens, Keltouma Driouch, Anaïs Boulai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 17, 2022
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study
Florence Dalenc, Amélie Lusque, Thibault De La Motte Rouge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 23, 2025
Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Séverine Guiu, Judith Balmaña, Pablo Lemercier, et al.
JAMA Oncology
|
November 5, 2020
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial
François-Clément Bidard, William Jacot, Nicolas Kiavue, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 139) with videos related to
Sort By:
Page
of 14
European Journal of Cancer (Oxford, England : 1990)
|
November 17, 2023
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort
Angéline Galvin, Coralie Courtinard, Fanny Bouteiller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
Hans Wildiers, Anne Armstrong, Eveline Cuypere, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2019
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup
Véronique D'Hondt, Jean-Luc Canon, Lise Roca, et al.
Lancet (London, England)
|
August 2, 2025
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial
Etienne Brain, Olivier Mir, Emmanuelle Bourbouloux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 11, 2017
Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper
Matti Aapro, Alain Astier, Riccardo Audisio, et al.
The Oncologist
|
August 17, 2023
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
Fanny Le Du, Matthieu Carton, Thomas Bachelot, et al.
Genome Medicine
|
March 16, 2021
Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study
Céline Callens, Keltouma Driouch, Anaïs Boulai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 17, 2022
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study
Florence Dalenc, Amélie Lusque, Thibault De La Motte Rouge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 23, 2025
Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Séverine Guiu, Judith Balmaña, Pablo Lemercier, et al.
JAMA Oncology
|
November 5, 2020
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial
François-Clément Bidard, William Jacot, Nicolas Kiavue, et al.
Page
of 14